drugset / Trial / NCT07861932
A Phase 1/2a Study of K-1728 in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This first-in-human, open-label, multicenter study evaluates K-1728 administered as monotherapy and in combination in participants with advanced or metastatic solid tumors. The study assesses the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of K-1728.
Timeline
- Start
- 2026-10
- Primary completion
- 2028-09
- Completion
- 2029-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | — | Intramuscular |
| Subject | K-1728 | Unknown | — | Oral |
| Subject | Palbociclib | Small molecule | — | Oral |